Reading this on a mobile device? Try our optimized mobile version here:

December 20, 2012
More than 2,700 companies nationwide are saving on lab supplies, shipping, news distribution, office products and more through the BIO Business Solutions cost-savings program. Find out how.

The news summaries appearing in BIO SmartBrief are based on original information from news organizations and are produced by SmartBrief, Inc., an independent e-mail newsletter publisher. The information is not compiled or summarized by BIO. Questions and comments should be directed to SmartBrief at

  Today's Top Story 
  • Analysis: U.S. life science R&D spending will grow to $189.3B in 2013
    The U.S. life science sector is expected to spend $189.3 billion in research and development in 2013, up from $181.6 billion this year, driven by improved access to data, according to an analysis by Battelle and R&D Magazine. Out of the 275 life science firms that responded to a survey, a majority anticipate their R&D investment to grow over 2012 and 40% said they would participate in more collaborative research next year. (12/19) LinkedInFacebookTwitterEmail this Story
Reimagine the life science patient experience
The life science industry is undergoing rapid transformation, driven by consumer empowerment, clinical innovation and outcomes-driven health care policy. In this changing landscape, medical device and pharmaceutical companies are striving to connect with patients and deliver the best possible experience before, during and after therapy. Learn more.
  Health Care & Policy 
  • FDA-approved trial to use telemonitoring, crowdsourcing approaches
    A Phase II clinical trial to examine the effectiveness of lisinopril in patients with multiple sclerosis by Transparency Life Sciences was approved by the FDA. The 12-month trial, which is the first to implement both remote monitoring and crowdsourcing techniques, will be performed by the biopharmaceutical startup with telehealth firm AMC Health. (12/18) LinkedInFacebookTwitterEmail this Story
  Company & Financial News 
  Industry Deals 
  Food & Agriculture 
  • EFSA supports safety of Monsanto's biotech maize pollen for food use
    A European Food Safety Authority panel concluded that Monsanto's MON 810 maize pollen is safe for use "in or as foods." "[T]he genetic modification in maize MON 810 does not constitute an additional health risk if maize MON 810 pollen is to replace maize pollen from non-GM maize in or as food," the panel said. The panel's scientific opinion supports Monsanto's application to bring the maize pollen in the market. FoodNavigator (12/19) LinkedInFacebookTwitterEmail this Story
  Industrial & Environmental 
  • House, Senate agree to keep Defense Dept.'s biofuels program
    The House of Representatives and the Senate have struck a deal to strip a provision from the defense authorization bill that would limit the military's ability to purchase biofuels. "This new compromise language will allow [the Department of Defense] to move forward with its clean energy agenda unscathed," said Stephanie Dreyer, a spokeswoman for the Truman National Security Project. The Hill/E2 Wire blog (12/18) LinkedInFacebookTwitterEmail this Story
  News from BIO 
  • BIOtechNOW
    BIOtechNOW is the first in a number of new products from BIO intended to enhance our communications with the biotech community -- not only with our members, but with other stakeholders as well. This e-newsletter, combined with its website, serves as our flagship in that effort. BIOtechNOW will offer original content that emphasizes the business needs of the industry; highlight BIO's advocacy efforts; and provide a portal to all BIO activities and events. Most importantly, it will spotlight for those outside the industry the value of biotechnology. Sign up for the e-newsletter. LinkedInFacebookTwitterEmail this Story
Learn more about BIO ->Conferences  |  Join BIO  |  Media  |  Issues  |  Industry

No man for any considerable period can wear one face to himself and another to the multitude, without finally getting bewildered as to which may be the true."
--Nathaniel Hawthorne,
American author

LinkedInFacebookTwitterEmail this Story

Subscriber Tools
Print friendly format | Web version | Search past news | Archive | Privacy policy

Account Director:  Meryl Harold (202) 407-7828
A powerful website for SmartBrief readers including:
 Recent BIO SmartBrief Issues:   Lead Editor:  Tom Parks
Mailing Address:
SmartBrief, Inc.®, 555 11th ST NW, Suite 600, Washington, DC 20004
© 1999-2012 SmartBrief, Inc.® Legal Information